Omega-3 Drug Vascepa Slows Progress of Heart Disease, New Study from The Lundquist Institute Shows

The Lundquist Institute investigator Dr. Matthew Budoff presented results at AHA conference

Study shows The Lundquist Institute is top-tier venue for pharmaceutical research

PHILADELPHIA — Findings from a new study provide a promising pathway toward reducing the impact of heart disease, as the data shows that Vascepa, a drug derived from omega-3 oils that is commonly used to treat hypertriglyceridemia, a disease that causes elevated fat levels in blood, also reduces the progression of heart disease.

For Detecting the Harmful Effects of HIV and Improving the Lives of COPD Patients, The Lundquist Institute Honors Two Physician-Scientists for Groundbreaking Research

Leading Biomedical Innovators Honored at The Lundquist Institute Legends Celebration 2019

LOS ANGELES – The Lundquist Institute, one of the nation’s leading nonprofit biomedical research institutes, hosted its 16th Annual Legends celebration on November 12 honoring two highly distinguished researchers for their groundbreaking innovations and outstanding service in finding solutions to the most pressing medical problems of our day.

Vaping Causes Lung Damage in Just 3 Days of Use, New Study Says

E-cigarette use, or vaping, can damage lungs in as little as three days of use, according to a new study from The Lundquist Institute (formerly known as LA BioMed) and the University of Rochester.

LOS ANGELES — E-cigarette use, or vaping, can damage lungs in as little as three days of use, according to a new study from The Lundquist Institute (formerly known as LA BioMed) and the University of Rochester.